Low-Dose Drug Combination Targets Senescent & Cancer Cells, Extends Lifespan in Aged Mice | Aging
Thumbnail from YouTube. Playing loads the YouTube player.
History & recommendationsOff
Keep recently viewed content on this browser. Your history stays on this device and is never sent to Harbor. Videos you play can also help order related video recommendations.
Open saved items & history →About this video
Creator description · original language
Aging #Published a new #Research Paper on July 17, 2026, in Volume 18, titled “Selective targeting of cancer and senescence via shared metabolic shifts extends lifespan of old mice,” by #Researchers from the Department of Bioengineering and QB3 Institute, UC Berkeley, Berkeley, CA. @BerkeleyNews
#Aging #Longevity #Cancer #Senolytics #CellularSenescence #OpenAccess #PeerReviewed #Publishing #MedEd
DOI - https://doi.org/10.18632/aging.206399
Corresponding author - Irina M. Conboy - irina@generationlab.co
Author presentation - https://www.youtube.com/watch?v=tke71MaAays
Longevity & Aging Series - https://www.youtube.com/watch?v=wllQRXPq_sY
Abstract
Eliminating both senescent and cancer cells through pharmacological intervention presents a powerful therapeutic strategy against aging and tumor progression. Navitoclax has emerged as a promising candidate with both senolytic and antitumor activity, but its clinical application remains limited due to dose-dependent thrombocytopenia and tumor-specific resistance. To overcome these limitations, we combined dichloroacetate and metformin with a 10-fold reduced dose of Navitoclax (ABT-263) and show that this pharmacology, termed, DMA, selectively targets the metabolic vulnerabilities underlying senescent and malignant cells. We demonstrate that DMA effectively ablates different types of senescent and cancer cells in vitro by exacerbating their defects in ATP production. Notably, the treatment is well tolerated by healthy human cells and in mice in vivo, and in fact improves the functional performance of aged mice after acute administration and extends lifespan after prolonged dosing. While the in vivo effects of DMA are yet to be fully explored, our findings suggest that it might represent a new, clinically viable way to combat cancer and senescence without toxicity to healthy cells and tissues.
Sign up for free Altmetric alerts about this article -
https://aging.altmetric.com/details/email_updates?id=10.18632%2Faging.206399
Subscribe for free publication alerts from Aging - https://www.aging-us.com/subscribe-to-toc-alerts
Keywords - aging, senescence, cancer, metabolic shift, ATP
To learn more about the journal, please visit https://www.Aging-US.com and connect with us on social media at:
Bluesky - https://bsky.app/profile/aging-us.bsky.social
ResearchGate - https://www.researchgate.net/journal/Aging-1945-4589
X - https://twitter.com/AgingJrnl
Facebook - https://www.facebook.com/AgingUS/
Instagram - https://www.instagram.com/agingjrnl/
LinkedIn - https://www.linkedin.com/company/aging/
Reddit - https://www.reddit.com/user/AgingUS/
Pinterest - https://www.pinterest.com/AgingUS/
YouTube - https://www.youtube.com/@Aging-US
Spotify - https://open.spotify.com/show/1X4HQQgegjReaf6Mozn6Mc
MEDIA@IMPACTJOURNALS.COM
Aging Journal · 2 min · Source published: 2026-08-03
Added to Harbor: 10/22/2026
Original on YouTube ↗Automatically categorized source. Creator statements are not an independent evidence review or personal medical guidance.